- Home
- LPTX vs XNET Comparison
LPTX vs XNET Comparison
Compare LPTX & XNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- XNET
- Stock Information
- Founded
- LPTX 2011
- XNET 2003
- Country
- LPTX United States
- XNET China
- Employees
- LPTX N/A
- XNET N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- XNET Computer Software: Prepackaged Software
- Sector
- LPTX Health Care
- XNET Technology
- Exchange
- LPTX Nasdaq
- XNET Nasdaq
- Market Cap
- LPTX 119.6M
- XNET 131.8M
- IPO Year
- LPTX N/A
- XNET 2014
- Fundamental
- Price
- LPTX $2.55
- XNET $2.12
- Analyst Decision
- LPTX Strong Buy
- XNET
- Analyst Count
- LPTX 3
- XNET 0
- Target Price
- LPTX $7.50
- XNET N/A
- AVG Volume (30 Days)
- LPTX 335.2K
- XNET 111.5K
- Earning Date
- LPTX 11-13-2024
- XNET 03-13-2025
- Dividend Yield
- LPTX N/A
- XNET N/A
- EPS Growth
- LPTX N/A
- XNET 146.84
- EPS
- LPTX N/A
- XNET 0.23
- Revenue
- LPTX N/A
- XNET $359,611,000.00
- Revenue This Year
- LPTX N/A
- XNET N/A
- Revenue Next Year
- LPTX N/A
- XNET N/A
- P/E Ratio
- LPTX N/A
- XNET $9.37
- Revenue Growth
- LPTX N/A
- XNET 99.13
- 52 Week Low
- LPTX $1.68
- XNET $1.45
- 52 Week High
- LPTX $4.79
- XNET $2.41
- Technical
- Relative Strength Index (RSI)
- LPTX 37.35
- XNET 54.45
- Support Level
- LPTX $2.88
- XNET $1.99
- Resistance Level
- LPTX $3.27
- XNET $2.17
- Average True Range (ATR)
- LPTX 0.28
- XNET 0.10
- MACD
- LPTX -0.06
- XNET 0.00
- Stochastic Oscillator
- LPTX 12.71
- XNET 83.02
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About XNET Xunlei Limited
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.